Search Existing Tissue Requests

The Knight ADRC has supported many investigators at Washington University and at other institutions over the years. We wish to avoid the situation where two investigators study the same research question to avoid duplication of effort and potential conflict. To determine if your topic has already been studied with our resources, please search our database. If you find that your topic or a related topic has been submitted, you may wish to contact the investigator to inquire about their findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID number (e.g. T1004), the full request has been submitted and is either approved, disapproved or in process. If an entry has no ID number, then it represents a submission that has not yet been reviewed. Search terms are applied across an entire requests application including variables not displayed below. A more specific, detailed search may yield better results depending upon your needs.


Search Terms:


Investigator: Nupam Mahajan

Project Title: Therapeutic Targeting of the Alzheimer’s Disease by Novel ACK1 Inhibitor (R)-9b

Date: December 17, 2025 at 5:32 pm

Request ID: T2524

Aim 1: Preclinical evaluation of pY827-ACK1 and pY394-Tau as novel therapeutic targets in AD

Aim 2:

Aim 3:

Aim 4:


Investigator: Zerui Wang

Project Title: Spatial and Cellular Mapping of α-Synuclein Seeding Activity in Human Synucleinopathies Using an In Situ Quiescent Seed Amplification Assay (QSAA)

Date: December 16, 2025 at 12:38 pm

Request ID: T2523

Aim 1: Construct spatial maps of α-synuclein seeding activity in human synucleinopathies

Aim 2: Define the cellular localization of α-synuclein seeding activity using IF-QSAA

Aim 3: Correlate functional seeding activity to classical α-synuclein pathology

Aim 4:


Investigator: Agnes Cheong

Project Title: Comprehensive Alzheimer’s Disease Research Initiative: Integrating Spatial Proteomics, Pathological Mechanisms, and Novel Therapeutic Target Discovery

Date: December 12, 2025 at 1:27 pm

Request ID: T2522

Aim 1: Neurite Protection Against Patient-Derived Bioactive Amyloid-Beta Species: Identifying Novel Therapeutic Targets for Alzheimer’s Disease and related diseases

Aim 2: Understanding Tau Pathology Heterogeneity: Implications for Targeted Therapeutic Strategies in Alzheimer’s Disease

Aim 3: Spatial molecular mapping of Alzheimer’s disease brain via MALDI-tMSI

Aim 4:


Investigator: Zhao Sun

Project Title: Dissecting molecular mechanism associated with the onset of late-onset neurodegenerative diseases.

Date: November 24, 2025 at 11:14 am

Request ID: T2521

Aim 1: Aim 1. Define the transcriptional and chromatin landscapes that distinguish healthy aging from pathological aging in LOAD neurons. With approval from the Alzheimer’s Disease Research Center at Washington University in St. Louis (hereafter “WashU ADRC”), we will obtain fibroblast lines from individua

Aim 2: Aim 2. Test partial rejuvenation can slow or reverse disease progression in LOAD. We will determine whether attenuating normal healthy aging can slow or reverse disease onset and progression in LOAD. To do this, we will apply partial epigenetic reprogramming (by transient Yamanaka-factor expression

Aim 3:

Aim 4:


Investigator: Gwendalyn Randolph

Project Title: Volumetric Mapping of Immune – Vascular Disruption in Human Cerebral Amyloid Angiopathy by ADAPT – 3D

Date: November 6, 2025 at 6:03 pm

Request ID: T2520

Aim 1: Determine the 3D spatial relationship between Aβ accumulation and BAM spatial reorganization and correlate these findings with available antemortem neuroimaging and fluid biomarkers.

Aim 2: Establish the volumetric correlation of vascular failure (smooth muscle cell loss and microhemorrhage) and validate these metrics against antemortem MRI/PET data and systemic biomarkers.

Aim 3:

Aim 4:


Investigator: Carlos Cruchaga

Project Title: Brain samples from the Neuropathological core to Cruchaga lab and Genetics and High Throughput -Omics Core

Date: October 23, 2025 at 9:56 am

Request ID: T2519

Aim 1: Aim 1. To collect participant biological materials, obtain and bank DNA and generated genetic information.

Aim 2: Aim 2: To extract RNA from all the brain samples in the Neuropath core

Aim 3:

Aim 4:


Investigator: Li-Huei Tsai

Project Title: Investigating Lipidomic Perturbations in the CSF with Age and Alzheimer’s Disease Progression: Toward Mechanistic Insights and Accessible Lipid Biomarkers

Date: October 15, 2025 at 3:41 pm

Request ID: T2518

Aim 1: Perform lipidomic profiling on longitudinal CSF samples from 75 ADRC Knight subjects using LC-MS based methods to identify lipid changes that occur with age and their association with CSF Abeta42/40 levels, sex, and APOE4 carrier status.

Aim 2:

Aim 3:

Aim 4:


Investigator: Carlos Cruchaag

Project Title: Longitudinal plasma proteomic studies in Alzheimer’s Disease

Date: October 15, 2025 at 11:28 am

Request ID: T2517

Aim 1: Identify proteomic profiles and biomarkers to progression to symptomatic AD and MCI-to-AD

Aim 2: Identify proteomic profiles associated with the rate of progression. i.e: fast vs slow progressors

Aim 3:

Aim 4:


Investigator: Jessica Mozersky & Sarah Hartz

Project Title: Comparative plasma validation

Date: September 17, 2025 at 3:57 pm

Request ID: T2515

Aim 1: Compare & map p-tau 217% measures from the Bateman lab to those from C2N

Aim 2:

Aim 3:

Aim 4:


Investigator: Carlos Cruchaga

Project Title: Large Scale Phosphoproteomics to identify novel biomarkers and causal targets

Date: September 14, 2025 at 11:24 am

Request ID: T2516

Aim 1: Identify plasma proteomic signatures and new prediction models for AD.

Aim 2: AI-driven multi-disease classifier

Aim 3: Identify potential causal and druggable proteins by using pQTL and Mendelian randomization, colocalization, and PWAS approaches.

Aim 4: